Navigation Links
Hormone Therapy May Cut Colorectal Cancer Risk
Date:1/8/2009

Study included nearly 57,000 women who had been followed for about 15 years

THURSDAY, Jan. 8 (HealthDay News) -- Hormone therapy may lower a woman's risk of colorectal cancer, especially if she is no longer taking the hormones.

This new finding, published in the January issue of Cancer Epidemiology, Biomarkers and Prevention, further complicates an already murky picture of the risks and benefits of hormone replacement therapy (HRT).

Previous landmark research has shown an increased risk of breast cancer and cardiovascular problems, but a lowered risk of colon cancer. More recent studies have found that the stage in life when a woman takes hormone therapy can influence the effect. The drugs are typically prescribed to women dealing with menopausal symptoms.

Other studies have also found a lowered risk of colon cancer among HRT users and, at this time, the weight of the evidence seems to point in that direction.

"These data do add additional weight to prior reports suggesting that hormone replacement therapy reduces the risk of colorectal cancer," said Dr. Neal Meropol, director of the Gastrointestinal Cancer Program at Fox Chase Cancer Center in Philadelphia.

But the studies have yet to translate into discoveries that can affect medical practice.

"This study highlights the complexity of systems that affect tumor development and growth, and raises the possibility that there will be pathways we can identify that can be specifically targeted that can be used to prevent and treat colon cancer," Meropol added. "These findings open the door to asking other fundamental questions about what causes colon cancers to develop, the results of which could provide clues to new prevention strategies."

The new study, led by researchers at the University of Minnesota School of Public Health, gleaned information on colorectal cancer incidence and hormone use from nearly 57,000 women who had been followed for about 15 years.

The researchers found a 17 percent reduced risk of colorectal cancer among women who had ever used estrogen alone, a 25 percent reduced risk among women currently using estrogen, and a 26 percent reduced risk among those using estrogen for 10 or more years.

Among women taking estrogen plus progestin, there was a 22 percent reduced risk, and a 45 percent reduced risk -- the highest seen -- among those who had stopped taking the combination hormones at least five years earlier.

The researchers also reported a 36 percent drop in risk among women who'd used progestin sequentially -- less than 15 days a month.

It's not clear what the biological mechanisms might be that could contribute to the reduction in risk.

"It appears that estrogens likely have direct or indirect effects on the growth of colonic epithelial cells," Meropol said.

More information

The Women's Health Initiative has more on the health effects of HRT in postmenopausal women.



SOURCES: Neal Meropol, M.D., director, Gastrointestinal Cancer Program, Fox Chase Cancer Center, Philadelphia; January 2009 Cancer Epidemiology, Biomarkers and Prevention


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Drop in breast cancer incidence linked to hormone use, not mammograms
2. Researchers develop long-lasting growth hormone
3. One of the Largest Post-WHI Physician Surveys Shows More Education is Needed: Patient Misinformation About Hormone Therapy Remains High
4. Less than one-third of women aware of landmark hormone therapy study, Stanford researcher finds
5. Most Women Unaware of Hormone Replacement Study
6. Survival data presented from phase II study of hormone-resistant prostate cancer patients
7. Hormone May Play Key Part in Creating Memories
8. Hormone Therapy for Prostate Cancer Linked to Heart Risks
9. Wyeth to Appeal Nevada Hormone Therapy Trial Verdict
10. New data on hormone therapy must lead to re-evaluation of official guidelines
11. From Hot Flashes to Breast Cancer: ZRT Labs Hormone Testing Catches On As Women Consider Safer, More Natural Options.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... ProVest Insurance ... greater Dallas, Miami, and Raleigh regions, is organizing an extended charity drive to ... and deadly chromosome abnormality. , After struggling since birth with several health challenges, ...
(Date:10/13/2017)... ... 13, 2017 , ... The American Board of Family Medicine's (ABFM) Board of ... Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. Newton will serve ... Puffer’s retirement at the end of 2018. Upon assuming the role of President and ...
(Date:10/13/2017)... ... 2017 , ... Lori R. Somekh, founder of the Law Office of ... elder law and special needs planning attorneys. “Membership in ElderCounsel helps our office remain ... to network with elder law attorneys nationwide,” said Somekh. , ElderCounsel ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Ellevate Network, ... in business to advocate for action towards gender equality at their inaugural Summit in ... around the globe, and reached a social audience of over 3 million. To watch ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader ... been awarded a contract by the Center for Medicare and Medicaid Services (CMS). ... the enterprise use of Agile methodologies in a consistent and high value manner ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host ... webcast on Friday, November 3, 2017, beginning at 7:00 ... approximately 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... performance and guidance for 2018, Hill-Rom executives will also ... performance, and long-range financial outlook through 2020. ...
(Date:9/27/2017)... NEW YORK , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: ... data solutions, today announced that its MyDario product is expected to appear ... listings for when The Dr. Oz Show airs in your area: ... The nine-time Emmy award-winning, The ... ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
Breaking Medicine Technology: